C4 Therapeutics appointed a new CMO, Dr. Adam Crystal, to oversee clinical development of its pipeline of protein degrader-based therapeutics.
Dr. Crystal was a medical oncologist at Massachusetts General Hospital prior to his most recent role at Novartis Institutes for BioMedical Research, where he led early development programs in oncology.
C4 has collaborations with Roche, Calico and Biogen to develop small molecule degraders targeting proteins implicated in a variety of disease types, including cancer, Alzheimer’s disease and Parkinson’s disease.
